These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33500715)

  • 21. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
    Ogunwobi OO; Puszyk W; Dong HJ; Liu C
    PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
    Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
    [No Abstract]   [Full Text] [Related]  

  • 24. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
    Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
    Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APC
    Shi M; Dai WQ; Jia RR; Zhang QH; Wei J; Wang YG; Xiang SH; Liu B; Xu L
    Cancer Lett; 2021 Jan; 496():144-155. PubMed ID: 33039559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
    Ang CS; Sun MY; Huitzil-Melendez DF; Chou JF; Capanu M; Jarnagin W; Fong Y; Dematteo RP; D'Angelica M; Allen P; Chen CT; O'Reilly EM; Weiser MR; Abou-Alfa GK
    Anticancer Res; 2013 Aug; 33(8):3241-5. PubMed ID: 23898085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.
    Heideman DA; Overmeer RM; van Beusechem VW; Lamers WH; Hakvoort TB; Snijders PJ; Craanen ME; Offerhaus GJ; Meijer CJ; Gerritsen WR
    Cancer Gene Ther; 2005 Dec; 12(12):954-62. PubMed ID: 15905856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma.
    Ko H; Huh G; Jung SH; Kwon H; Jeon Y; Park YN; Kim YJ
    Food Chem Toxicol; 2020 Aug; 142():111475. PubMed ID: 32522589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
    Korhan P; Erdal E; Atabey N
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
    Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
    Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
    Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.
    Zhang Y; Gao X; Zhu Y; Kadel D; Sun H; Chen J; Luo Q; Sun H; Yang L; Yang J; Sheng Y; Zheng Y; Zhu K; Dong Q; Qin L
    J Exp Clin Cancer Res; 2018 Apr; 37(1):93. PubMed ID: 29712569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transmembrane protein 106C promotes the development of hepatocellular carcinoma.
    Luo X; Han G; Lu R; Guan S; Wang Y; Ju L; Chen L; Shao J; Bian Z
    J Cell Biochem; 2020 Nov; 121(11):4484-4495. PubMed ID: 32037603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.
    Jiang J; Liu Z; Ge C; Chen C; Zhao F; Li H; Chen T; Yao M; Li J
    J Biol Chem; 2017 Nov; 292(47):19146-19159. PubMed ID: 28972178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.